• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Hepatic resection for large hepatocellular carcinoma in the era of UCSF criteria.UCSF 标准时代的大肝癌肝切除术。
HPB (Oxford). 2009 Nov;11(7):551-8. doi: 10.1111/j.1477-2574.2009.00084.x.
2
Hepatic resection for transplantable hepatocellular carcinoma for patients within Milan and UCSF criteria.米兰和 UCSF 标准范围内的移植性肝细胞癌患者的肝切除术。
Am J Clin Oncol. 2012 Apr;35(2):141-5. doi: 10.1097/COC.0b013e318209ab7d.
3
Living donor liver transplantation or hepatic resection combined with intraoperative radiofrequency ablation for Child-Pugh A hepatocellular carcinoma patient with Multifocal Tumours Meeting the University of California San Francisco (UCSF) criteria.活体肝移植或肝切除术联合术中射频消融治疗符合加利福尼亚大学旧金山分校 (UCSF) 标准的多灶性肿瘤 Child-Pugh A 期肝细胞癌患者。
J Cancer Res Clin Oncol. 2021 Feb;147(2):607-618. doi: 10.1007/s00432-020-03364-x. Epub 2020 Aug 27.
4
Comparison of Hepatic Resection Combined with Intraoperative Radiofrequency Ablation, or Hepatic Resection Alone, for Hepatocellular Carcinoma Patients with Multifocal Tumors Meeting the University of California San Francisco (UCSF) Criteria: A Propensity Score-Matched Analysis.比较符合加利福尼亚大学旧金山分校(UCSF)标准的多灶性肝癌患者行肝切除术联合术中射频消融与单纯肝切除术的疗效:倾向评分匹配分析。
Ann Surg Oncol. 2020 Jul;27(7):2334-2345. doi: 10.1245/s10434-020-08231-0. Epub 2020 Feb 3.
5
[Surgical treatment of primary liver cancer:a report of 10 966 cases].[原发性肝癌的外科治疗:10966例报告]
Zhonghua Wai Ke Za Zhi. 2021 Jan 1;59(1):6-17. doi: 10.3760/cma.j.cn112139-20201110-00791.
6
Long-term outcomes after resection versus transplantation for hepatocellular carcinoma within UCSF criteria.UCSF 标准下肝切除术与肝移植治疗肝细胞癌的长期疗效比较。
Ann Surg Oncol. 2012 Mar;19(3):826-33. doi: 10.1245/s10434-011-1975-x. Epub 2011 Aug 31.
7
Model for End-stage Liver Disease score fails to predict perioperative outcome after hepatic resection for hepatocellular carcinoma in patients without cirrhosis.终末期肝病模型评分无法预测无肝硬化的肝细胞癌患者肝切除术后的围手术期结局。
Am J Surg. 2008 May;195(5):697-701. doi: 10.1016/j.amjsurg.2007.05.054.
8
Effect of Liver Transplant on Long-term Disease-Free Survival in Children With Hepatoblastoma and Hepatocellular Cancer.肝移植对儿童肝母细胞瘤和肝细胞癌患者无病长期生存的影响。
JAMA Surg. 2015 Dec;150(12):1150-8. doi: 10.1001/jamasurg.2015.1847.
9
Outcomes of Liver Transplantation for Hepatocellular Carcinoma Beyond the University of California San Francisco Criteria: A Single-center Experience.加利福尼亚大学旧金山标准之外的肝癌肝移植治疗结果:单中心经验。
Transplantation. 2020 Jan;104(1):113-121. doi: 10.1097/TP.0000000000002835.
10
Hepatocellular carcinoma downstaging in liver transplantation.肝移植中肝细胞癌的降期
Transplant Proc. 2012 Mar;44(2):412-4. doi: 10.1016/j.transproceed.2012.01.043.

引用本文的文献

1
CircRNA and Stroke: New Insight of Potential Biomarkers and Therapeutic Targets.环状 RNA 与中风:潜在生物标志物和治疗靶点的新视角。
Neurochem Res. 2024 Mar;49(3):557-567. doi: 10.1007/s11064-023-04077-6. Epub 2023 Dec 8.
2
Multidrug-resistant bacterial infection in adult patients following cardiac surgery: clinical characteristics and risk factors.成人心脏手术后耐多药细菌感染:临床特征和危险因素。
BMC Cardiovasc Disord. 2023 Sep 21;23(1):472. doi: 10.1186/s12872-023-03488-1.
3
A Systematic Review and Meta-Analysis Comparing Liver Resection with the Rf-Based Device Habib™-4X with the Clamp-Crush Technique.一项比较使用基于射频的Habib™-4X设备进行肝切除术与钳夹挤压技术的系统评价和荟萃分析。
Cancers (Basel). 2018 Nov 8;10(11):428. doi: 10.3390/cancers10110428.
4
Resection and radiofrequency ablation in the treatment of hepatocellular carcinoma: a single-center experience.切除与射频消融治疗肝细胞癌:单中心经验。
Surg Endosc. 2012 Apr;26(4):990-7. doi: 10.1007/s00464-011-1983-8. Epub 2011 Oct 25.

本文引用的文献

1
Model for end-stage liver disease (MELD) score, as a prognostic factor for post-operative morbidity and mortality in cirrhotic patients, undergoing hepatectomy for hepatocellular carcinoma.终末期肝病模型(MELD)评分是预测行肝癌切除术的肝硬化患者术后发病率和死亡率的预后因素。
HPB (Oxford). 2009 Jun;11(4):351-7. doi: 10.1111/j.1477-2574.2009.00067.x.
2
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis.预测米兰标准以外的肝细胞癌患者肝移植后的生存率:一项回顾性探索性分析。
Lancet Oncol. 2009 Jan;10(1):35-43. doi: 10.1016/S1470-2045(08)70284-5. Epub 2008 Dec 4.
3
Surgical resection of hepatocellular carcinoma.肝细胞癌的手术切除
Cancer J. 2008 Mar-Apr;14(2):100-10. doi: 10.1097/PPO.0b013e31816a5c1f.
4
Surgical treatment of hepatocellular carcinoma beyond Milan criteria. Results of liver resection, salvage transplantation, and primary liver transplantation.米兰标准以外的肝细胞癌的外科治疗。肝切除、挽救性移植和原位肝移植的结果。
Ann Surg Oncol. 2008 May;15(5):1383-91. doi: 10.1245/s10434-008-9851-z. Epub 2008 Mar 5.
5
Radiofrequency-assisted liver resection.射频辅助肝切除术
Surg Oncol. 2008 Aug;17(2):81-6. doi: 10.1016/j.suronc.2007.10.046. Epub 2007 Dec 3.
6
Palliation of hepatic tumors.肝肿瘤的姑息治疗。
Surg Oncol. 2007 Dec;16(4):277-91. doi: 10.1016/j.suronc.2007.08.010. Epub 2007 Nov 1.
7
Current treatment strategy for hepatocellular carcinoma.肝细胞癌的当前治疗策略。
Saudi Med J. 2007 Sep;28(9):1330-8.
8
Longterm favorable results of limited hepatic resections for patients with hepatocellular carcinoma: 20 years of experience.肝细胞癌患者行局限性肝切除术的长期良好结果:20年经验
J Am Coll Surg. 2007 Jul;205(1):19-26. doi: 10.1016/j.jamcollsurg.2007.01.069.
9
Liver resection for hepatocellular carcinoma in a hepatitis B endemic area.乙肝高发地区肝细胞癌的肝切除术
World J Surg. 2007 Sep;31(9):1775-1781. doi: 10.1007/s00268-007-9069-4. Epub 2007 Jul 4.
10
Salvage living donor liver transplantation after prior liver resection for hepatocellular carcinoma.先前因肝细胞癌行肝切除术后的挽救性活体肝移植。
Liver Transpl. 2007 May;13(5):741-6. doi: 10.1002/lt.21157.

UCSF 标准时代的大肝癌肝切除术。

Hepatic resection for large hepatocellular carcinoma in the era of UCSF criteria.

出版信息

HPB (Oxford). 2009 Nov;11(7):551-8. doi: 10.1111/j.1477-2574.2009.00084.x.

DOI:10.1111/j.1477-2574.2009.00084.x
PMID:20495706
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2785949/
Abstract

BACKGROUND

Treating patients with hepatocellular carcinoma (HCC) remains a challenge, especially when the disease presents at an advanced stage. The aim of this retrospective study was to determine the efficacy of liver resection in patients who fulfil or exceed University of California San Francisco (UCSF) criteria by assessing longterm outcome.

METHODS

Between 2002 and 2008, 59 patients with large HCC (>5 cm) underwent hepatectomy. Thirty-two of these patients fulfilled UCSF criteria for transplantation (group A) and 27 did not (group B). Disease-free survival and overall survival rates were compared between the two groups after resection and were critically evaluated with regard to patient eligibility for transplant.

RESULTS

In all patients major or extended hepatectomies were performed. There was no perioperative mortality. Morbidity consisted of biliary fistula, abscess, pleural effusion and pneumonia and was significantly higher in patient group B. Disease-free survival rates at 1, 3 and 5 years were 66%, 37% and 34% in group A and 56%, 29% and 26% in group B, respectively (P < 0.01). Survival rates at 1, 3 and 5 years were 73%, 39% and 35% in group A and 64%, 35% and 29% in group B, respectively (P= 0.04). The recurrence rate was higher in group B (P= 0.002).

CONCLUSIONS

Surgical resection, if feasible, is suggested in patients with large HCC and can be performed with acceptable overall and disease-free survival and morbidity rates. In patients eligible for transplantation, resection may also have a place in the management strategy when waiting list time is prolonged for reasons of organ shortage or when the candidate has low priority as a result of a low MELD (model for end-stage liver disease) score.

摘要

背景

治疗肝细胞癌(HCC)患者仍然是一个挑战,尤其是当疾病处于晚期时。本回顾性研究的目的是通过评估长期结果来确定符合或超过加利福尼亚大学旧金山分校(UCSF)标准的患者行肝切除术的疗效。

方法

2002 年至 2008 年间,59 例大肝癌(>5cm)患者接受了肝切除术。其中 32 例患者符合 UCSF 移植标准(A 组),27 例不符合(B 组)。切除后比较两组患者的无病生存率和总生存率,并根据患者的移植资格对其进行严格评估。

结果

所有患者均行主要或扩大肝切除术。无围手术期死亡。并发症包括胆瘘、脓肿、胸腔积液和肺炎,B 组患者的发病率明显更高。A 组患者的 1、3 和 5 年无病生存率分别为 66%、37%和 34%,B 组分别为 56%、29%和 26%(P<0.01)。A 组患者的 1、3 和 5 年生存率分别为 73%、39%和 35%,B 组分别为 64%、35%和 29%(P=0.04)。B 组的复发率更高(P=0.002)。

结论

如果可行,对于大肝癌患者,建议进行手术切除,其总生存率和无病生存率以及发病率均可以接受。对于符合移植条件的患者,当因器官短缺而延长等待名单时间或由于低 MELD(终末期肝病模型)评分导致候选者优先级较低时,切除术也可能在管理策略中占有一席之地。